Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

About this update from Sonoma Pharmaceuticals, Inc.

[{"type":"text","content":"BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, today announced that it has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).","length":434,"tagName":"p"},{"type":"text","content":"The MoCRA registration expands Sonoma's regulatory footprint, enabling the Company to manufacture and commercialize Microcyn technology products as cosmetics in the United States. Sonoma's manufacturing facility is already FDA-registered as a medical device establishment, supporting Sonoma's portfolio of FDA 510(k)-cleared products across wound care, dermatology, eye care, podiatry, and animal health. The MoCRA registration builds on this foundation and provides Sonoma with increased access to the rapidly growing U.S. cosmetics and dermatology consumer markets.","length":579,"tagName":"p"},{"type":"text","content":"According to industry reports, the U.S. skin care market is projected to reach nearly $40 billion by 2030. Sonoma's patented hypochlorous acid technology, its proven safety record, and its effectiveness for many common skin conditions uniquely address the increased consumer demand for clean, technology-driven skincare solutions.","length":334,"tagName":"p"},{"type":"text","content":""Sonoma's robust regulatory expertise allows us to bring safe, effective products to market across multiple healthcare categories," said Amy Trombly, CEO of Sonoma. "This new MoCRA registration positions us to increase our reach in the fast-growing U.S. cosmetics and dermatology markets with Microcyn-based products, creating meaningful opportunities for growth and value creation."","length":407,"tagName":"p"},{"type":"text","content":"About Sonoma Pharmaceuticals, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Sonoma Pharmaceuticals is a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, dermatological conditions, eye, oral and nasal care, podiatry, animal health care, and non-toxic disinfectants. Sonoma's prod...

More updates from Sonoma Pharmaceuticals, Inc.